Atezolizumab Plus Bevacizumab & Chemotherapy in First-Line Metastatic

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Status Completed

Clinical Trial Summary

This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.

This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC. ;

NCT number	NCT05261438
Study type	Observational
Source	Hunan Province Tumor Hospital
Contact
Status	Completed
Phase
Start date	September 1, 2019
Completion date	September 15, 2021

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04413201` - AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC	Phase 4
Active, not recruiting	`NCT04447118` - Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy	Phase 3
Recruiting	`NCT03755869` - Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）	Phase 4
Withdrawn	`NCT04466917` - A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer	Phase 3
Not yet recruiting	`NCT05782426` - Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC	Phase 2
Recruiting	`NCT05751187` - Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients	Phase 2
Terminated	`NCT02454842` - Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients	Phase 2
Not yet recruiting	`NCT06206850` - Neo-Bio-ADAURA: A Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib	Phase 2